BSD Medical Reports Initiation of a Clinical Study to Treat Recurrent Rectal Cancer With the BSD-2000

Published: Dec 17, 2012

SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) reports initiation of a Phase I/II clinical study (HyRec-Trial) using the BSD-2000 Hyperthermia System (BSD-2000) to deliver hyperthermia in combination with chemotherapy (5-FU/oxaliplatin) and radiotherapy for the treatment of patients with locally recurrent rectal cancer. The multicenter study, which will be sponsored by the University of Erlangen Medical School (Erlangen), will evaluate the feasibility and the efficacy of adding hyperthermia to a multimodal treatment regimen that includes potent new chemotherapeutic agents such as oxaliplatin. The study will initially enroll 59 patients. If the study parameters are met, a randomized Phase III clinical trial will be initiated. The HyRec-Trial has been approved by the German Cancer Society.

Back to news